NASDAQ:OMIC Singular Genomics Systems (OMIC) Stock Price, News & Analysis → How a $0.25 cent option contract makes my top traders feel (From DTI) (Ad) Free OMIC Stock Alerts $0.40 -0.01 (-3.04%) (As of 02:37 PM ET) Add Compare Share Share Today's Range$0.39▼$0.4050-Day Range$0.38▼$0.6152-Week Range$0.31▼$1.21Volume8,948 shsAverage Volume114,339 shsMarket Capitalization$29.26 millionP/E RatioN/ADividend YieldN/APrice Target$0.68 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Singular Genomics Systems alerts: Email Address Singular Genomics Systems MarketRank™ Stock AnalysisAnalyst RatingHold2.00 Rating ScoreUpside/Downside70.9% Upside$0.68 Price TargetShort InterestHealthy1.42% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.36Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.63 out of 5 starsMedical Sector436th out of 907 stocksAnalytical Instruments Industry15th out of 26 stocks 3.0 Analyst's Opinion Consensus RatingSingular Genomics Systems has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageSingular Genomics Systems has only been the subject of 1 research reports in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted1.42% of the float of Singular Genomics Systems has been sold short.Short Interest Ratio / Days to CoverSingular Genomics Systems has a short interest ratio ("days to cover") of 5.3.Change versus previous monthShort interest in Singular Genomics Systems has recently decreased by 17.62%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldSingular Genomics Systems does not currently pay a dividend.Dividend GrowthSingular Genomics Systems does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for OMIC. Previous Next 1.9 News and Social Media Coverage News SentimentSingular Genomics Systems has a news sentiment score of 0.36. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Singular Genomics Systems this week, compared to 0 articles on an average week.MarketBeat FollowsOnly 1 people have added Singular Genomics Systems to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Singular Genomics Systems insiders have not sold or bought any company stock.Percentage Held by Insiders21.90% of the stock of Singular Genomics Systems is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions65.80% of the stock of Singular Genomics Systems is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Singular Genomics Systems is -0.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Singular Genomics Systems is -0.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSingular Genomics Systems has a P/B Ratio of 0.16. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Prosper Trading AcademyThese AI trades triggered this morning (545% return)If you think a market crash is possible in 2024, I don't know why you're not using this yet. Click Here To Get Your Free Copy About Singular Genomics Systems Stock (NASDAQ:OMIC)Singular Genomics Systems, Inc., a life science technology company, develops next generation sequencing and multiomics technology for researchers and clinicians to advance science and medicine. The company is involved in the developing of G4, consisting of G4 instrument and associated consumables for various applications, such as max read kits for single cell sequencing, rare variant detection with high-definition sequencing, gene fusion detection with ring-seq, and extended range sequencing; and PX instrument and associated consumables for applications comprising single cell gene expression and proteomics, in situ RNA sequencing, and spatial RNA and proteomics applications for tissue. Singular Genomics Systems, Inc. was incorporated in 2016 and is based in San Diego, California.Read More OMIC Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart OMIC Stock News HeadlinesApril 20, 2024 | investing.comSingular Genomics Systems Inc (OMIC)April 17, 2024 | msn.comSingular Genomics Systems (OMIC) Price Target Increased by 25.93% to 0.87April 25, 2024 | Wall Street Star (Ad)This Apple-like Innovator is Revolutionizing HealthcareAI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.April 4, 2024 | msn.comDeciphering genomic language: New AI system unlocks biology’s source codeMarch 20, 2024 | seekingalpha.comSingular Genomics Systems, Inc. (OMIC) Q4 2023 Earnings Call TranscriptMarch 20, 2024 | finance.yahoo.comSingular Genomics Systems, Inc. (NASDAQ:OMIC) Q4 2023 Earnings Call TranscriptMarch 19, 2024 | finanznachrichten.deSingular Genomics Systems, Inc.: Singular Genomics Reports Recent Highlights and Fourth Quarter and Full Year 2023 Financial ResultsMarch 18, 2024 | benzinga.comSingular Genomics Sys: Q4 Earnings InsightsApril 25, 2024 | Banyan Hill Publishing (Ad)The Best AI Stock to Own in the World Today is Trading for Just $25“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.March 18, 2024 | globenewswire.comSingular Genomics Reports Recent Highlights and Fourth Quarter and Full Year 2023 Financial ResultsMarch 17, 2024 | markets.businessinsider.comSingular Genomics Systems earnings: here's what to expectMarch 15, 2024 | benzinga.comPreview: Singular Genomics Sys's EarningsMarch 15, 2024 | msn.comSingle-cell RNA-seq reveals transcriptomic modulation of Alzheimer's disease by activated protein CMarch 11, 2024 | msn.comNovel gene editing tool analyzes sperm health in animalsMarch 5, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Ginkgo Bioworks Holdings (DNA), ZimVie Inc (ZIMV) and Veeva Systems (VEEV)March 4, 2024 | globenewswire.comSingular Genomics to Report Fourth Quarter and Full Year 2023 Financial Results on March 18, 2024February 24, 2024 | wsj.comSingular Genomics Systems Inc.February 5, 2024 | finanznachrichten.deSingular Genomics Systems, Inc.: Singular Genomics Unveils G4X Spatial Sequencer, Transforming the Landscape of In Situ Multiomic AnalysisJanuary 8, 2024 | msn.comSingular Genomics reports instrument shipments, preliminary Q4 revenueJanuary 7, 2024 | finance.yahoo.comSingular Genomics Reports Instrument Shipments and Preliminary Unaudited Fourth Quarter 2023 RevenueJanuary 4, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Illumina (ILMN), Pfizer (PFE) and Neurogene (NGNE)November 21, 2023 | finance.yahoo.comSingular Genomics Systems Founder Acquires 4.6% More StockNovember 16, 2023 | markets.businessinsider.comHold Rating on Singular Genomics Systems (OMIC) Amid Q3 Underperformance and Strategy ShiftNovember 16, 2023 | finanznachrichten.deSingular Genomics Systems, Inc.: Singular Genomics Reports Recent Highlights and Third Quarter 2023 Financial ResultsNovember 14, 2023 | benzinga.comRecap: Singular Genomics Sys Q3 EarningsNovember 14, 2023 | seekingalpha.comOMIC Singular Genomics Systems, Inc.November 4, 2023 | morningstar.comSingular Genomics Systems Inc OMICSee More Headlines Receive OMIC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Singular Genomics Systems and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/18/2024Today4/25/2024Next Earnings (Estimated)5/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Analytical instruments Sub-IndustryN/A Current SymbolNASDAQ:OMIC CUSIPN/A CIK1850906 Websingulargenomics.com Phone858-333-7830FaxN/AEmployees255Year FoundedN/APrice Target and Rating Average Stock Price Target$0.68 High Stock Price Target$0.85 Low Stock Price Target$0.50 Potential Upside/Downside+68.8%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($1.31) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-94,820,000.00 Net Margins-3,257.30% Pretax Margin-3,257.30% Return on Equity-45.33% Return on Assets-33.29% Debt Debt-to-Equity Ratio0.05 Current Ratio10.51 Quick Ratio9.77 Sales & Book Value Annual Sales$2.91 million Price / Sales10.18 Cash FlowN/A Price / Cash FlowN/A Book Value$2.44 per share Price / Book0.16Miscellaneous Outstanding Shares74,080,000Free Float57,860,000Market Cap$29.62 million OptionableOptionable Beta1.39 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesMr. Andrew Spaventa (Age 39)Founder, CEO, President & Chairperson of the Board Comp: $685.93kDr. David L. Barker Ph.D. (Age 82)Founder, Member of Scientific Advisory Board & Independent Director Comp: $63.75kDr. Eli N. Glezer Ph.D. (Age 55)Founder, Chief Scientific Officer & Chair of Scientific Advisory Board Comp: $496.5kMr. Dalen Meeter (Age 46)Chief Financial Officer Comp: $434.39kJyotsna GhaiChief Operating OfficerMr. Jorge Velarde Jr. (Age 57)MBA, Senior Vice President of Corporate Development & Strategy Mr. Jeff BullardHead of SalesMr. Vincent Brancaccio (Age 41)Head of Human Resources Mr. Samuel Ropp Ph.D. (Age 50)Chief Commercial Officer More ExecutivesKey CompetitorsCue HealthNASDAQ:HLTHCara TherapeuticsNASDAQ:CARARapid Micro BiosystemsNASDAQ:RPIDAccelerate DiagnosticsNASDAQ:AXDXBionano GenomicsNASDAQ:BNGOView All CompetitorsInsiders & InstitutionsPerceptive Advisors LLCSold 236,321 shares on 2/26/2024Ownership: 2.898%Weil Company Inc.Bought 20,000 shares on 2/9/2024Ownership: 0.188%Simplex Trading LLCBought 1,000 shares on 2/2/2024Ownership: 0.000%Eli N GlezerBought 200,000 shares on 11/16/2023Total: $86,000.00 ($0.43/share)Andrew SpaventaBought 43,468 shares on 11/16/2023Total: $17,821.88 ($0.41/share)View All Insider TransactionsView All Institutional Transactions OMIC Stock Analysis - Frequently Asked Questions Should I buy or sell Singular Genomics Systems stock right now? 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Singular Genomics Systems in the last twelve months. There are currently 2 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" OMIC shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in OMIC, but not buy additional shares or sell existing shares. View OMIC analyst ratings or view top-rated stocks. What is Singular Genomics Systems' stock price target for 2024? 2 Wall Street analysts have issued 1 year price objectives for Singular Genomics Systems' stock. Their OMIC share price targets range from $0.50 to $0.85. On average, they anticipate the company's share price to reach $0.68 in the next twelve months. This suggests a possible upside of 70.9% from the stock's current price. View analysts price targets for OMIC or view top-rated stocks among Wall Street analysts. How have OMIC shares performed in 2024? Singular Genomics Systems' stock was trading at $0.4601 at the beginning of the year. Since then, OMIC stock has decreased by 14.1% and is now trading at $0.3950. View the best growth stocks for 2024 here. Are investors shorting Singular Genomics Systems? Singular Genomics Systems saw a decline in short interest in the month of April. As of April 15th, there was short interest totaling 603,300 shares, a decline of 17.6% from the March 31st total of 732,300 shares. Based on an average daily volume of 113,500 shares, the short-interest ratio is presently 5.3 days. Approximately 1.4% of the shares of the company are sold short. View Singular Genomics Systems' Short Interest. When is Singular Genomics Systems' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our OMIC earnings forecast. How were Singular Genomics Systems' earnings last quarter? Singular Genomics Systems, Inc. (NASDAQ:OMIC) announced its quarterly earnings results on Monday, March, 18th. The company reported ($0.34) EPS for the quarter. The business earned $1.08 million during the quarter. Singular Genomics Systems had a negative trailing twelve-month return on equity of 45.33% and a negative net margin of 3,257.30%. When did Singular Genomics Systems IPO? Singular Genomics Systems (OMIC) raised $178 million in an initial public offering on Thursday, May 27th 2021. The company issued 8,500,000 shares at a price of $20.00-$22.00 per share. J.P. Morgan, Goldman Sachs, BofA Securities, Cowen and UBS Investment Bank served as the underwriters for the IPO. How do I buy shares of Singular Genomics Systems? Shares of OMIC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:OMIC) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldHe Is Giving Away BitcoinCrypto Swap ProfitsYour Money is Not SafeAmerican Alternative Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Singular Genomics Systems, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
